Oral drug for the treatment of cutaneous T cell lymphoma who have progressive, persistent or recurrent disease.
A histone deacetylase (HDAC) inhibitor that inhibits the enzymatic activity of HDAC1, HDAC2, HDAC3 and HDAC6.
Decreased HDAC activity believed to allow activation of genes that may help slow or stop growth of cancer cells.
Belongs to the class of hydroxamic acid containing hybrid polar molecules.
Can lead to down regulation of the expression of various oncogenes, such associated BCR/ABL, c-MYC, and HDAC3 in myeloid leukemia cell lines.
Toxicities include fatigue and nausea.
Dehydration can occur and recommended that patient have at least 2 liters of fluid per day.
Utilization has been associated with thrombocytopenia, anemia and thromboembolism.
Recommended dose is 400 mg orally, given once daily with food as 4 100 mg capsules.
Treatment may be continued until evidence of progression or intolerance.
The following Vorinostat side effects occur in greater than 30% of patients.
Fatigue
Diarrhea
Nausea
Taste changes
Increased blood glucose level
Increased creatinine level
Increased level of protein in the urine
Low platelet count
Less common side effects, occurring in about 10-29%, of patients.
Loss of appetite
Weight loss
Muscle spasms
Hair loss
Dry mouth
Chills
Fever
Vomiting
Dizziness
Constipation
Anemia
Headache
Itching
Swelling in hands or feet
Cough
Upper respiratory infection
Dehydration
Shortness of breath